Adverse drug reactions associated with doxorubicin and epirubicin: A descriptive analysis from VigiBase.

Deborah A Matesun Kofi Boamah MensahPeter YamoahVarsha BangaleeNeelaveni Padayachee

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2022)

This study provides relevant global insights into serious ADRs for doxorubicin and epirubicin. This knowledge may assist in minimizing and proactively managing ADRs. It can also inform policies to improve patients' quality of life.

Keyphrases

adverse drug
end stage renal disease
ejection fraction
drug delivery
newly diagnosed
chronic kidney disease
healthcare
public health
prognostic factors
cross sectional
electronic health record